NutraSift: The nutraceutical innovation podcast

Cranberry- A-type vs. B-type proanthocyanidins: the same molecule class, different linkage, completely different function

5 min · Eilen
jakson Cranberry- A-type vs. B-type proanthocyanidins: the same molecule class, different linkage, completely different function kansikuva

Kuvaus

Cranberry has A-type PACs (anti-adhesion); grape seed has B-type PACs (antioxidant/vascular). The only structural difference is one additional ether bond between flavanol units. That single bond changes the entire biological function. Most consumers and many companies don't know there are two types, let alone that they do completely different things. Publications of interest: https://pmc.ncbi.nlm.nih.gov/articles/PMC10215713/, https://pmc.ncbi.nlm.nih.gov/articles/PMC3823508/, https://pmc.ncbi.nlm.nih.gov/articles/PMC8389005/

Kommentit

0

Ole ensimmäinen kommentoija

Rekisteröidy nyt ja liity NutraSift: The nutraceutical innovation podcast-yhteisöön!

Aloita maksutta

14 vrk ilmainen kokeilu

Kokeilun jälkeen 7,99 € / kuukausi. · Peru milloin tahansa.

  • Podimon podcastit
  • 20 kuunteluaikaa / kuukausi
  • Lataa offline-käyttöön

Kaikki jaksot

76 jaksot

jakson Can we actually reverse aging? Scientists just put it to the test in humans. kansikuva

Can we actually reverse aging? Scientists just put it to the test in humans.

This week, the first patient was dosed in a landmark trial of ER-100, the first cellular reprogramming therapy to reach people. We unpack the science behind "making cells young again": how three Yamanaka transcription factors reset the epigenetic clock without touching your DNA, why dropping the cancer-linked one matters, and the clever doxycycline "off-switch" that makes it safe enough for the clinic. Then the practical aspects. Gene therapy is reversal in the clinic, but what about the rest population? We dig into where natural bioactives fit for everyday prevention, why ingredient synergy beats single molecules, and how AI is bringing personalized formulations to longevity. Publications of interest: World-first: therapy to make cells young again trialled in a person [https://www.nature.com/articles/d41586-026-01836-7]  https://www.lifebiosciences.com/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies/ [https://]  https://clinicaltrials.gov/study/NCT07290244 [https://]  https://www.technologynetworks.com/biopharma/articles/re-setting-the-epigenetic-clock-to-reverse-cellular-aging-413392

10. kesä 20268 min